205 related articles for article (PubMed ID: 37296624)
1. Genome-Wide Screening in Human Embryonic Stem Cells Highlights the Hippo Signaling Pathway as Granting Synthetic Viability in ATM Deficiency.
Viner-Breuer R; Golan-Lev T; Benvenisty N; Goldberg M
Cells; 2023 May; 12(11):. PubMed ID: 37296624
[No Abstract] [Full Text] [Related]
2. Targeting p38 mitogen-activated protein kinase signaling restores subventricular zone neural stem cells and corrects neuromotor deficits in Atm knockout mouse.
Kim J; Wong PK
Stem Cells Transl Med; 2012 Jul; 1(7):548-56. PubMed ID: 23197859
[TBL] [Abstract][Full Text] [Related]
3. ATM modulates subventricular zone neural stem cell maintenance and senescence through Notch signaling pathway.
Dong C; Wang X; Sun L; Zhu L; Yang D; Gao S; Zhang W; Ling B; Liang A; Gao Z; Xu J
Stem Cell Res; 2022 Jan; 58():102618. PubMed ID: 34915311
[TBL] [Abstract][Full Text] [Related]
4. Inactive Atm abrogates DSB repair in mouse cerebellum more than does Atm loss, without causing a neurological phenotype.
Tal E; Alfo M; Zha S; Barzilai A; De Zeeuw CI; Ziv Y; Shiloh Y
DNA Repair (Amst); 2018 Dec; 72():10-17. PubMed ID: 30348496
[TBL] [Abstract][Full Text] [Related]
5. ATM loss disrupts the autophagy-lysosomal pathway.
Cheng A; Tse KH; Chow HM; Gan Y; Song X; Ma F; Qian YXY; She W; Herrup K
Autophagy; 2021 Aug; 17(8):1998-2010. PubMed ID: 32757690
[TBL] [Abstract][Full Text] [Related]
6. ATM-deficient human neural stem cells as an in vitro model system to study neurodegeneration.
Carlessi L; Fusar Poli E; De Filippis L; Delia D
DNA Repair (Amst); 2013 Aug; 12(8):605-11. PubMed ID: 23707302
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of Cytoplasmic DNA Due to ATM Deficiency Activates the Microglial Viral Response System with Neurotoxic Consequences.
Song X; Ma F; Herrup K
J Neurosci; 2019 Aug; 39(32):6378-6394. PubMed ID: 31189575
[TBL] [Abstract][Full Text] [Related]
8. Ataxia telangiectasia syndrome: moonlighting ATM.
Zaki-Dizaji M; Akrami SM; Abolhassani H; Rezaei N; Aghamohammadi A
Expert Rev Clin Immunol; 2017 Dec; 13(12):1155-1172. PubMed ID: 29034753
[TBL] [Abstract][Full Text] [Related]
9. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
Gulliver C; Hoffmann R; Baillie GS
Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
[TBL] [Abstract][Full Text] [Related]
10. Correction of ATM mutations in iPS cells from two ataxia-telangiectasia patients restores DNA damage and oxidative stress responses.
Ovchinnikov DA; Withey SL; Leeson HC; Lei UW; Sundarrajan A; Junday K; Pewarchuk M; Yeo AJ; Kijas AW; Lavin MF; Wolvetang EJ
Hum Mol Genet; 2020 Apr; 29(6):990-1001. PubMed ID: 32037450
[TBL] [Abstract][Full Text] [Related]
11. The innate immune response transcription factor relish is necessary for neurodegeneration in a Drosophila model of ataxia-telangiectasia.
Petersen AJ; Katzenberger RJ; Wassarman DA
Genetics; 2013 May; 194(1):133-42. PubMed ID: 23502677
[TBL] [Abstract][Full Text] [Related]
12. Dysfunction of cerebellar microglia in Ataxia-telangiectasia.
Levi H; Bar E; Cohen-Adiv S; Sweitat S; Kanner S; Galron R; Mitiagin Y; Barzilai A
Glia; 2022 Mar; 70(3):536-557. PubMed ID: 34854502
[TBL] [Abstract][Full Text] [Related]
13. ATM splicing variants as biomarkers for low dose dexamethasone treatment of A-T.
Menotta M; Biagiotti S; Spapperi C; Orazi S; Rossi L; Chessa L; Leuzzi V; D'Agnano D; Soresina A; Micheli R; Magnani M
Orphanet J Rare Dis; 2017 Jul; 12(1):126. PubMed ID: 28679388
[TBL] [Abstract][Full Text] [Related]
14. Atm reactivation reverses ataxia telangiectasia phenotypes in vivo.
Di Siena S; Campolo F; Gimmelli R; Di Pietro C; Marazziti D; Dolci S; Lenzi A; Nussenzweig A; Pellegrini M
Cell Death Dis; 2018 Feb; 9(3):314. PubMed ID: 29472706
[TBL] [Abstract][Full Text] [Related]
15. Ataxia-telangiectasia: A review of clinical features and molecular pathology.
Amirifar P; Ranjouri MR; Yazdani R; Abolhassani H; Aghamohammadi A
Pediatr Allergy Immunol; 2019 May; 30(3):277-288. PubMed ID: 30685876
[TBL] [Abstract][Full Text] [Related]
16. Disease severity in a mouse model of ataxia telangiectasia is modulated by the DNA damage checkpoint gene Hus1.
Balmus G; Zhu M; Mukherjee S; Lyndaker AM; Hume KR; Lee J; Riccio ML; Reeves AP; Sutter NB; Noden DM; Peters RM; Weiss RS
Hum Mol Genet; 2012 Aug; 21(15):3408-20. PubMed ID: 22575700
[TBL] [Abstract][Full Text] [Related]
17. A rat model of ataxia-telangiectasia: evidence for a neurodegenerative phenotype.
Quek H; Luff J; Cheung K; Kozlov S; Gatei M; Lee CS; Bellingham MC; Noakes PG; Lim YC; Barnett NL; Dingwall S; Wolvetang E; Mashimo T; Roberts TL; Lavin MF
Hum Mol Genet; 2017 Jan; 26(1):109-123. PubMed ID: 28007901
[TBL] [Abstract][Full Text] [Related]
18. The appropriateness of the mouse model for ataxia-telangiectasia: neurological defects but no neurodegeneration.
Lavin MF
DNA Repair (Amst); 2013 Aug; 12(8):612-9. PubMed ID: 23731731
[TBL] [Abstract][Full Text] [Related]
19. Neurodegeneration in ataxia-telangiectasia: Multiple roles of ATM kinase in cellular homeostasis.
Choy KR; Watters DJ
Dev Dyn; 2018 Jan; 247(1):33-46. PubMed ID: 28543935
[TBL] [Abstract][Full Text] [Related]
20. A novel mouse model for ataxia-telangiectasia with a N-terminal mutation displays a behavioral defect and a low incidence of lymphoma but no increased oxidative burden.
Campbell A; Krupp B; Bushman J; Noble M; Pröschel C; Mayer-Pröschel M
Hum Mol Genet; 2015 Nov; 24(22):6331-49. PubMed ID: 26310626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
